TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Pomerantz Llp
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

Pomerantz LLP is investigating potential securities fraud claims against Ventyx Biosciences following the company's December 2, 2025 announcement that it was delaying topline data release from its Phase 2 recurrent pericarditis trial to Q1 2026. The delay announcement triggered a 15.35% stock price decline, falling from approximately $9.38 to $7.94 per share.

Insights
NVDA   neutral

Earnings results anticipated this week, with market watching closely


VTYX   negative

The company faces a securities fraud investigation following a significant stock price decline (15.35%) triggered by the announcement of a clinical trial data delay. The delay and subsequent investigation suggest potential investor concerns about misleading guidance or undisclosed material information.